Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has announced the departure of independent director Patrick Ashe, who had been instrumental in steering the company through its initial development phase.
Following his exit, Eddie Gibson will take over as chair of the audit and risk committee. Additionally, professor Brendan Buckley will assume the role of chair of the remuneration committee.
Chairman Cathal Friel said: "We would like to thank Patrick for his contribution since joining at the IPO, where his knowledge and experience of growing biopharma companies has been of considerable value.
"Patrick joined the company as part of its IPO and steps down from the board at a time when Poolbeg is on an upward trajectory with a robust pipeline of high-value programmes, and at a particularly exciting juncture following the recent appointment of three key former Amryt Pharma leadership members to the Poolbeg team with the view to replicating the success they had with Amryt.
"With a strong financial position, excellent clinical results achieved and productive partnering discussions ongoing, the company is well positioned to generate significant shareholder value."